Thymosin Alpha-1 / Thymalfasin
N-Terminally Acetylated 28-Amino-Acid Thymic Peptide
Thymosin Alpha-1 is an immune- and thymic-peptide research subject within Alford Molecular Research's Research Compound Library. This molecular profile outlines technical characteristics and translational signaling contexts for nonclinical research objectives.
Chemical Class
N-terminally acetylated 28-amino-acid thymic peptide
Primary Research Domain
Immune & Thymic Peptides
Evidence Classification
Supported, with interpretation dependent on indication and endpoint
Primary Research Areas
innate immune signaling; adaptive immune signaling; dendritic-cell biology; T-cell-associated responses; Toll-like-receptor-associated pathways; cytokine-signaling networks; antigen-presentation biology; immune-response modulation
Molecular Data Card
Compound
Thymosin Alpha-1
Aliases
Thymalfasin; Tα1; TA1
Class
N-terminally acetylated 28-amino-acid thymic peptide
CAS Number
62304-98-7
Formula
C129H215N33O55
Molar Mass
3108.29 g/mol
Terminals
N-Term: Acetylated | C-Term: Free carboxyl
Sequence
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
Molecular Identity
Thymosin Alpha-1 is a 28-amino-acid peptide derived from prothymosin-alpha biology and is characterized by an N-terminal acetyl group. N-terminal acetylation is an essential part of the molecular identity and should not be treated as optional within research contexts.
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
Structural Identity Requirement
Thymosin Alpha-1 should be defined by its full 28-amino-acid sequence together with its N-terminal acetylation state.
Molecular Target / Mechanism
Thymosin Alpha-1 research biology is framed around complex immune-regulatory signaling networks rather than a single-receptor model. Experimental investigations focus on its involvement in innate immune signaling, adaptive immune signaling, and dendritic-cell biology. The peptide is associated with multiple pathways, including T-cell-associated responses, Toll-like-receptor-associated pathways, cytokine-signaling networks, and antigen-presentation biology. Current evidence suggests that Thymosin Alpha-1 exerts its research effects through immune-response modulation across these integrated signaling systems, rather than via one exclusive canonical receptor.
Intracellular Signaling Context
Thymosin Alpha-1 has been investigated in immune-signaling systems involving dendritic cells, T-cell responses, Toll-like-receptor-associated pathways, cytokine networks, and other innate/adaptive immune mechanisms. Biological activity in research models is observed across these pathways, and no single intracellular cascade or specific binding affinity has been established as the exclusive driver of its observed activity. Mechanistic interpretations should account for this poly-pathway association rather than implying a singular intracellular mechanism.
Cellular & Tissue-Level Research
Research involving dendritic-cell maturation and signaling; T-cell function; antigen presentation; innate immune recognition; adaptive immune response; cytokine regulation; and immune-system coordination. Molecular investigation is strictly mechanistic and research-oriented.
Innate Immune Signaling
Research examining early immune-recognition and innate immune-response pathways.
Toll-Like-Receptor-Associated Signaling
Research examining pathways associated with innate immune recognition and downstream signaling.
Adaptive Immunity
Experimental and clinical research involving T-cell-associated and adaptive immune responses.
Cytokine Networks
Study of immune-signaling molecules and the regulation of inflammatory and adaptive responses.
Dendritic-Cell Biology
Investigation of antigen-presenting cells and immune-response coordination.
Translational Immunology
Investigation of Thymosin Alpha-1 across infectious-disease, immune-dysregulation, oncology-supportive, and other clinical research contexts.
Translational Evidence Chain
Thymosin Alpha-1
→
Immune-Signaling Networks
→
Dendritic/T-Cell & Innate Immune Responses
→
Cellular Immune Modulation
→
Tissue/System Immune Response
→
Immunologic Biomarkers
→
Clinical or Functional Outcomes
Each downstream step requires independent evidence. Changes in immune signaling or biomarkers do not automatically establish meaningful clinical benefit.
Evidence Assessment
Evidence Classification: Supported
Thymosin Alpha-1 has human clinical and pharmacologic research across multiple indications and jurisdictions. Evidence quality varies substantially by disease state, study design, population, and endpoint. Findings from one infectious, immune, oncology-supportive, or other context should not automatically be generalized to unrelated uses; mechanistic immune effects do not establish generalized wellness or "immune boosting" benefit; and regulatory status and approved uses vary internationally. Alford Molecular Research evaluates Thymosin Alpha-1 evidence by indication rather than treating all immune-related claims as equivalent.
Example Analytical Documentation
Alford Molecular Research has reviewed third-party analytical documentation for Thymosin Alpha-1 research material including molecular identity, quantitative content, purity, and related quality-control testing. Analytical results are lot-specific and should not be generalized to other batches.
Structural / Formulation Considerations
Exact molecular interpretation may depend on N-terminal acetylation, C-terminal state, counterion, hydration state, and gross versus net peptide reporting. Sequence identity, acetylation state, chromatographic purity, quantitative peptide content, and salt state are analytically distinct quality attributes.
Analytical & Quality-Control Considerations
- Identity by Mass Spectrometry (MS)
- RP-HPLC or UPLC purity confirmation
- Exact 28-amino-acid sequence confirmation
- N-terminal acetylation confirmation
- C-terminal free carboxyl state verification
- Quantitative net peptide content
- Counterion / salt state analysis
- Residual solvents and water content
- Degradation products and aggregation profiles
- Endotoxin and sterility testing where relevant
N-Terminal Acetylation Control
Thymosin Alpha-1 is N-terminally acetylated. Analytical identity should confirm this modification because loss, omission, or misassignment of the acetyl group changes the defined molecular entity.
Stability & Handling — Scientific Context
Peptide stability is sensitive to moisture, light, and temperature. Repeated freeze-thaw cycles and compromised container integrity can accelerate peptide degradation. Research materials should be managed under conditions that preserve sequence integrity and molecular state.
Research & Regulatory Context
Thymosin Alpha-1 / thymalfasin has been investigated in human clinical research and has had regulatory or clinical use in some jurisdictions outside the United States. Regulatory status, indication, formulation, and commercial availability vary by country and can change over time. The existence of clinical use in one jurisdiction or indication does not establish efficacy for unrelated immune, wellness, longevity, or generalized preventive applications. Alford Molecular Research evaluates the molecular and translational evidence separately from commercial or promotional claims.
RESEARCH CONTEXT NOTICE
THIS INFORMATION IS FOR SCIENTIFIC AND RESEARCH CONTEXT ONLY. RESEARCH COMPOUNDS DESCRIBED ARE NOT INTENDED FOR THE TREATMENT, DIAGNOSIS, CURE, OR PREVENTION OF ANY DISEASE. THESE MATERIALS ARE NOT FOR HUMAN USE, CLINICAL ADMINISTRATION, OR DIAGNOSTIC PROCEDURES.